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Mutations in the mucolipin-1 gene have been linked to
mucolipidosis type IV, a lysosomal storage disorder char-
acterized by severe neurological and ophthalmologic
abnormalities. Mucolipin-1 is a membrane protein con-
taining six putative transmembrane domains with both
its N- and C-termini localized facing the cytosol. To gain
information on the sorting motifs that mediate the traf-
ficking of this protein to lysosomes, we have generated
chimeras in which the N- and C- terminal tail portions
of mucolipin-1 were fused to a reporter gene. In this
article, we report the identification of two separate di-
leucine-type motifs that co-operate to regulate the trans-
port of mucolipin-1 to lysosomes. One di-leucine motif is
positioned at the N-terminal cytosolic tail and mediates
direct transport to lysosomes, whereas the other di-
leucine motif is found at the C-terminal tail and functions
as an adaptor protein 2-dependent internalization motif.
We have also found that the C-terminal tail of mucolipin-
1 is palmitoylated and that this modification might
regulate the efficiency of endocytosis. Finally, the muta-
genesis of both di-leucine motifs abrogated lysosomal
accumulation and resulted in cell-surface redistribution
of mucolipin-1. Taken together, these results reveal
novel information regarding the motifs that regulate
mucolipin-1 trafficking and suggest a role for palmitoyla-
tion in protein sorting.
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Mucolipidosis type IV (MLIV) is an autosomal recessive
neurodegenerative lysosomal storage disorder character-
ized by psychomotor retardation and visual impairment (1).
Symptoms usually appear in the first year of life and
include progressive mental and motor deterioration, cor-
neal clouding, retinal degeneration and strabismus (2,3).
This disorder is found at a relative high frequency among
Ashkenazi Jews, with 1/100 of the population estimated
to be a genetic carrier (4). The analysis of fibroblasts from
MLIV patients by electron microscopy revealed the
presence of enlarged vacuolar structures that accumulate
phospholipids, mucopolysaccharides and gangliosides and
display a higher pH than normal lysosomes (5–8). In
contrast with most lysosomal storage disorders, lyso-
somal hydrolases in MLIV are normal and the accumula-
tion of the observed material seems to result from defects
in transport along the lysosomal pathway (9,10).
Linkage analysis carried out in 13 Ashkenazi Jewish families
mapped the MLIV locus to chromosome 19p13.3-p13.2 (11)
and allowed the identification of MCOLN1 as the gene
responsible for the disease (12–14). MCOLN1 encodes a
580-amino acid protein named mucolipin-1 with a predicted
molecular weight of 65 kDa. Mucolipin-1 is a membrane
protein containing six putative transmembrane domains
and both N- and C-termini facing the cytosol. Homology
studies reveal that mucolipin-1 is related to transient recept-
or potential channels, a heterogeneous family of proteins
known for their ability to conduct monovalent and divalent
cations (15). This homology has led to the suggestion that
mucolipin-1 functions as an ion channel. In agreement with
this idea, the expression of the protein in oocytes or artificial
liposomes demonstratedthat mucolipin-1behaves as a non-
selective cationchannelpermeable toCa
2þ,Na
þ and K
þ and
that its activity is modulated by changes in pH and Ca
2þ
concentration (16,17).
Recently, it has been proposed that mucolipin-1 may be
involved in the regulation of lysosome biogenesis, and
specifically, the reformation of lysosomes from endosome–
lysosome hybrid organelles (18). Consistent with this idea,
loss-of-function mutations in cup-5, the Caenorhabditis ele-
gans ortholog of mucolipin-1, resulted in enlarged vacuoles
that resemble endosome–lysosome hybrid organelles based
on the presence of both late endosomal and lysosomal mar-
kers (19–21).
To elucidate the mechanisms underlying the pathology
of MLIV, we analyzed the intracellular trafficking of
mucolipin-1. To date, little is known about the targeting
information that regulates the transport of this protein to
lysosomes or the motifs that mediate interaction with
the intracellular sorting machinery. To address these
questions, we have generated cDNA constructs encoding
chimeric proteins with isolated cytosolic domains of
mucolipin-1 attached to a reporter molecule (Tac) or
encoding full-length mucolipin-1 with mutations in putative
targeting motifs. This strategy has allowed us to identify
two independent di-leucine motifs that regulate the deliv-
ery of mucolipin-1 to lysosomes. One di-leucine motif is
located at the N-terminal tail, and it appears to promote
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337the transport of mucolipin-1 from the trans-Golgi
network (TGN) to early endosomes and subsequently to
lysosomes. In contrast, the other di-leucine motif is pre-
sent at the end of the C-terminal tail and functions as an
adaptor protein 2 (AP2)-dependent internalization motif.
We have also found that the C-terminal tail of mucolipin-1
is palmitoylated and that this modification may regulate the
efficiency of endocytosis.
Results
The C-terminal cytoplasmic tail of mucolipin-1 is
sufficient for targeting to early endosomes
To assess whether targeting information is present in the
C-terminalcytoplasmictail of mucolipin-1,a chimericprotein
was created in which the last 63 residues of mucolipin-1
were appended to the lumenal and transmembrane
domains of Tac, a cell-surface type 1 transmembrane
glycoprotein that has been used previously in chimeric
constructs to analyze carboxyl-terminal cytoplasmic
targeting signals (22). The localization of the chimeric
protein, termed Tac-MLN-CTail (for Tac lumenal-Tac
transmembrane-Mucolipin-1 C-terminal cytoplasmic tail),
was compared with that of intact Tac by indirect immuno-
fluorescence microscopy in HeLa cells using antibodies
directed to the Tac lumenal domain. Figure 1A shows
that although Tac was distributed mostly at the cell
surface with very little in internal structures, Tac-
MLN-CTailwaspresentmostlyinvesiclesscatteredthrough
the cytoplasm.
To further characterize the compartment to which the C-
terminal tail of mucolipin-1 targeted the Tac antigen, we
performed double staining by indirect immunofluorescence
analysis to co-localize Tac-MLN-CTail with various endo-
genous and transfected molecules. As seen in Figure 1B,
the Tac-MLN-CTail chimera showed a clear co-localization
with early endosomal markers, such as internalized
transferrin, Hrs, Rab5-green fluorescent protein (Rab5-
GFP) or its constitutively active version, Rab5-Q79L-GFP.
Conversely, no co-localization was observed with late
endosomal or lysosomal markers (Supplementary Material,
Figure S1). It is interesting to note that the
over-expression of Tac-MLN-CTail resulted in swollen
endosomes. However, this enlargement did not seem to
affect the trafficking of EGF or transferrin (our unpub-
lished results).
Identification of a targeting motif in the C-terminal
cytosolic tail of mucolipin-1
It has been previously described that most lysosomal
proteins have short cytosolic tails containing tyrosine or
di-leucine-based motifs that determine their lysosomal
targeting (23). The analysis of the C-terminal cytoplasmic
tail of mucolipin-1 revealed the presence of several puta-
tive sorting motifs. These include a YXXf motif (Y
521DTI),
a di-leucine motif (L
563L) and an acidic di-leucine motif
(D/E)XXXL(L/I) (E
573EHSLL) (Figure 2A). To determine
whether these or other signals were responsible for tar-
geting Tac-MLN-CTail to endosomes, we mutated the
three motifs individually by substitution of key residues
to alanines, and the resulting immunofluorescence profiles
were analyzed in transiently transfected HeLa cells.
Figure 2B shows that the mutation of Leu577 and
Leu578 to alanines (Tac-MLN-CTail-L
577L/AA) caused the
protein to be retained at the plasma membrane, whereas
the substitution of Tyr521 (Tac-MLN-CTail-Y
521/A) or
Leu563 (Tac-MLN-CTail-L
563/A) with alanines had no
effect on the distribution of the chimeras.
To determine whether the (D/E)XXXL(L/I) motif acts as a
signal for internalization from the cell surface, we per-
formed antibody-uptake experiments. Antibodies to Tac
were bound on ice to the surface of HeLa cells expressing
Tac, Tac-MLN-CTail or Tac-MLN-CTail-L
577L/AA, then
bound antibody was allowed to internalize for 15 min at
37  C, and the amount of protein remaining at the cell
surface was quantified by flow cytometry (FACS). As
seen in Figure 2C, nearly 60% of the antibody initially
bound to Tac-MLN-CTail was internalized by 15 min. In
contrast, no internalization was observed for the Tac-
MLN-CTail-L
577L/AA chimera. These data indicate that the
E
573EHSLL sequence is an essential component of the
endosomal targeting signal in mucolipin-1 cytoplasmic tail.
Endocytosis of Tac-MLN-CTail is dependent on
clathrin adaptor AP2
It has been extensively studied that (D/E)XXXL(L/I) motifs
are recognized with high specificity by the AP complexes.
Four different AP complexes have been described and
termed AP1, AP2, AP3 and AP4. Although all four com-
plexes participate in cargo selection and vesicle formation
in the endocytic and secretory pathways, they exhibit dis-
tinct intracellular localizations. AP2 is exclusively located at
the plasma membrane and plays an essential role in the
endocytosis of specific cargo proteins. To address whether
AP2 participates in the internalization of the Tac-MLN-CTail
chimera, we reduced the expression of endogenous AP2 in
HeLa cells using specific siRNA oligonucleotides.
Immunoblot analysis revealed a 90% reduction in the levels
of AP2 when compared with cells transfected with control
(non-silencing) siRNA (Figure 3A). The levels of annexin-II
were monitored as control for the specificity of the anti-
sense. As expected, HeLa cells depleted of AP2 showed
very little internalization of rhodamine-transferrin when
compared with control cells, indicating that AP2-dependent
endocytosis is impaired (Figure 3B). Likewise, FACS ana-
lysis revealed that the internalization of Tac-MLN-CTail was
blocked in the absence of AP2. Figure 3C shows that in
cells treated with control non-silencing siRNA approxi-
mately 35% of Tac-MLN-CTail remained at the plasma
membrane after 15 min internalization. In contrast, almost
no endocytosis of Tac-MLN-CTail was observed in
cells depleted of AP2. In addition, surface staining of
Vergarajauregui and Puertollano
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the chimera and AP2-GFP in structures that resemble
clathrin-coated-pits (Figure 3D). Altogether, these results
indicate that the E
573EHSLL sequence can mediate the
internalization of Tac-MLN-CTail through an AP2-depen-
dent pathway.
Palmitoylation mediates the association of the
C-terminal tail of mucolipin-1 with membranes
We found that the C-terminal cytosolic tail of mucolipin-1 is
sufficient to promote the recruitment of GFP to intracellular
membranes. Asseen inSupplementary Material,F i g u r ea n d
Figure 4A, the expression of a chimera containing the
Tac
B
A
Tac-MLN-CTail
Transferrin Tac-MLN-CTail merge
Hrs Tac-MLN-CTail merge
Rab5-Q79L-GFP Tac-MLN-CTail merge
Rab5-wt-GFP Tac-MLN-CTail merge
Figure 1: The C-terminal tail of
mucolipin-1 contains sorting
information for location to early
endosomes. (A) HeLa cells were
transfected with plasmids encoding
Tac alone (left panel) or a chimera
made by fusing the C-terminal tail of
mucolipin-1 to the extracellular and
transmembrane domains of Tac
(Tac-MLN-CTail) (right panel). Refer
to Figure 2A for the schematic of
the chimera. (B) HeLa cells were
transfected with plasmids encoding
Tac-MLN-CTail alone (first and sec-
ond row) or in combination with
Rab5-Q79L-GFP or Rab5-GFP (third
and fourth row, respectively).
Transfected cells were fixed, per-
meabilized and immunostained with
a monoclonal antibody to Tac fol-
lowed by a Cy3-conjugated donkey
anti-mouse IgG (for double immuno-
fluorescence with GFP) or an
Alexa488-conjugated goat anti-
mouse IgG (for double staining with
transferrin and Hrs). Cells were
examined by confocal fluorescence
microscopy. For transferrin staining,
cells wereincubated with rhodamine-
transferrin for 15 min at 37  C. For
Hrs staining, cells were incubated
with a polyclonal antibody to Hrs
followed by an Alexa555-conjugated
goat anti-rabbit IgG. Merging images
in the red and green channels
generated the third picture on each
row; yellow indicates overlapping
localization. Scale bar represents
10 mm.
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showed staining of the plasma membrane and cytosolic
vesicles. The vesicles strongly co-localized with early endo-
somal markers such as internalized transferrin, EEA1 and
Hrs, as well as with Tac-MLN-CTail (Supplementary
Material, Figure S2). These data indicate that the C-terminal
tail of mucolipin-1 has the ability to associate with mem-
branes independently of the presence of a transmembrane
domain, suggesting that acylation may be responsible for
the observed sub-cellular targeting.
Our examination of the sequence of the mucolipin-1
C-terminal tail revealed the presence of four cysteines
(C
561SLLCCC) that appear to be likely candidates to
undergo palmitoylation via thioester linkages. To assess
whether palmitoylation might be responsible for the asso-
ciation of the mucolipin-1 C-terminal tail with intracellular
membranes, we incubated HeLa cells expressing GFP-
MLN-CTail for 12 h with 2-bromopalmitate (2-BP), a potent
inhibitor of protein palmitoylation (24). As predicted, in
cells treated with 2-BP, GFP-MLN-CTail exhibited no
detectable membrane staining but instead displayed a
diffuse cytoplasmic staining (Figure 4A). Next, we carried
out systematic mutagenesis of the C
561SLLCCC sequence
by individually substituting each of these residues with
alanines and analyzing the location of the resulting
H2N-
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Figure 2: Adi-leucinemotiflocated
at C-terminal tail of mucolipin-1
mediates internalization of Tac-
MLN-CTail chimera. (A) Putative
sorting motifs present at the C-
terminal tail of mucolipin-1 and sorting
motif mutations to alanines. The
lumenal and transmembrane (TM)
domains of Tac as well as the C-
terminal tail of mucolipin-1 (Cyt) are
indicated. (B) Wild-type Tac-
MLN-CTail or Tac-MLN-CTail carrying
the indicated mutations was transi-
ently expressed in HeLa cells, incu-
bated for 1 h on ice with monoclonal
antibodies to the extracellular domain
ofTac,washedandallowedtointernal-
izefor15 minat37  C.Cellswerethen
fixed, permeabilized, stained with a
Cy3-conjugated donkey anti-mouse
IgG and analyzed by confocal fluores-
cence microscopy. Bar represents
10 mm. (C) Cell-surface levels of
Tac, Tac-MLN-CTail or Tac-MLN-Ctail-
L
577L/AA were analyzed by FACS, as
described in Materials and Methods.
Results are expressed as the percent-
age of Tac chimera remaining at
thecellsurfaceafter15 minincubation
at 37  C. Values represent the
mean   SD from four independent
experiments.
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marized in Table 1 Interestingly, the substitution of the
three cysteine residues located between positions 565
and 567 with alanines (GFP-MLN-CTail-C
565CC/AAA)
abolished the ability of the C-terminal tail of mucolipin-1
to associate with membranes (Table 1; Figure 4A).
Individual mutation of each of these three cysteines
revealed that Cys566 is essential for recruitment to
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Figure 3: Endocytosis of Tac-MLN-CTail is dependent on clathrin adaptor AP2. (A) HeLa cells were transfected with siRNA targeted
to control (non-silencing) or to the m2 subunit of the AP2 complex. Seventy-two hours after the second round of transfection, equivalent
amounts of homogenate from control and siRNA-treated cells were subjected to SDS-PAGE and immunoblotted using antibodies to the
b2 subunit of AP2 or annexin-II (loading control). (B) Control and siRNA-treated HeLa cells were incubated with rhodamine-transferrin for
15 min at 37  C and analyzed by confocal microscopy. (C) HeLa cells treated with non-targeted siRNA or siRNA against AP2 were
transfected with Tac-MLN-Ctail, and the amount of the chimera present at the plasma membrane was quantified by FACS analysis.
Results are expressed as the percent of Tac-MLN-CTail remaining at the cell surface after 15 min incubation at 37  C. Values represent
the mean   SD from two independent experiments. (D) HeLa cells were co-transfected with Tac-MLN-CTail and AP2-GFP, incubated for
1 h on ice with monoclonal antibody to the extracellular domain of Tac, washed and allowed to internalize for 1 min at 37  C. Cells were
then fixed, permeabilized, stained with a Cy3-conjugated donkey anti-mouse IgG and analyzed by confocal fluorescence microscopy.
Insets show a fourfold magnification of the indicated region. Bars represent 10 mm.
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Figure 4: Palmitoylation of three cysteine residues mediates recruitment of GFP-MLN-CTail to membranes. (A) HeLa cells
were transfected with either GFP-MLN-CTail, in the presence of ethanol or the inhibitor of palmitoylation 2-bromopalmitate (2-BP), or
GFP-MLN-CTail-C
565CC/AAA and analyzed by confocal microscopy. (B) Transfected HeLa cells were fractionated into cytosol (C) and
membrane fractions (M). The distribution of GFP-MLN-CTail in the presence or absence of 2-BP, and GFP-MLN-Tail-C
565CC/AAA was
determined by immunoblotting using a GFP-specific antibody. Equivalent volumes of cytosol and membrane fractions were loaded. (C)
Quantification of the optical densities of the corresponding GFP bands averaged from (B) from two independent experiments. (D) HeLa
cells were transfected with either GFP-MLN-CTail or GFP-MLN-CTail-L
577L/AA and analyzed by confocal microscopy. Bars represent
10 mm.
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had only a partial effect on the ability of the chimeras to
interact with intracellular membranes. The mutation of
Leu564 to alanine also caused redistribution to the cytosol,
suggesting that this amino acid is required for optimal
palmitoylation. In contrast, the substitution of Cys561,
Ser562 or Leu563 with alanine did not affect the distribu-
tion of the chimeras. Interestingly, a mutant that lacks the
last 13 residues but still contains Cys565, Cys566 and
Cys567 retained its ability to associate with membranes
but was localized exclusively to the plasma membrane.
Similarly, the substitution of Leu577 and Leu578 with
alanine also resulted in the redistribution of chimera to
the plasma membrane (Figure 4D). These data suggest
that the C
565CC sequence is required for palmitoylation
and subsequent association with membranes although the
acidic di-leucine motif mediates localization at endosomes.
To further confirm the role of palmitoylation on the mem-
brane partitioning of the GFP chimeras, we fractionated
cellular lysates from cells expressing the above chimeras
into cytosolic (C) and membrane (M) fractions through
high-speed ultracentrifugation. Figure 4B,C shows that
approximately 50% of GFP-MLN-CTail partitioned into
the membrane-associated fractions, whereas GFP-MLN-
CTail-C
565CC/AAA was predominantly soluble. The treat-
ment of cells expressing GFP-MLN-CTail with 2-BP also
caused the redistribution of chimera to the soluble frac-
tion. In comparison, non-palmitoylated Rab5 localization
was not altered by 2-BP treatment, indicating that the
drug is specific in blocking modification by palmitate
(data not shown). These results corroborate that prevent-
ing palmitoylation by cysteine-to-alanine mutations or 2-BP
treatment blocks the ability of the C-terminal tail of
mucolipin-1 to stably bind to membranes.
Palmitoylation regulates the efficiency of
internalization of Tac-MLN-CTail
It has been described that the position of sorting motifs
relative to the transmembrane domain may influence the
affinity of the interaction with the sorting machinery (23). In
the case of endocytic signals, they are often (although not
always) situated at proximity from the membrane. This
proximity could facilitate the interaction of AP2 with specific
lipids such as phosphatidylinositol 4,5-biphosphate (PIP2) or
other PIP2-binding proteins. Interestingly, the proximity of a
sorting motif to the membrane may be shortened by palmi-
toylation. It has been reported that the palmitoylation of
specific cysteine residues in the cytosolic tail of the
cation-dependent mannose 6-phosphate receptor may
serve to anchor this domain closer to the membrane by
insertion of the palmitoyl chains into the lipid bilayer (25).
Consistent with this idea, we hypothesized that palmitoy-
lation of the C
565CC site could help bring the E
573EHSLL
signal closer to the plasma membrane, thus facilitating
endocytosis. To address this possibility, we compared
the efficiency of internalization of Tac, Tac-MLN-CTail
and Tac-MLN-CTail-C
565CC/AAA by FACS. As shown in
Figure 5, the percent of Tac-MLN-CTail-C
565CC/AAA that
is internalized after 15 min was reduced to almost half
when compared with that of Tac-MLN-Ctail (35% versus
61%). Together, our results suggest that the palmitoyla-
tion of the C-terminal tail of mucolipin-1 may play a role in
regulating its trafficking possibly through bringing the
endocytic signal closer to the plasma membrane, thus
increasing the efficiency of endocytosis.
To test whether full-length mucolipin-1 was palmitoylated,
we transfected mucolipin-1 wild-type (MLN-GFP; see below)
as well as a mutant lacking the putative palmitoylated
cysteines (MLN-GFP-C
565CC/AAA) into HeLa cells and meta-
bolically labeled these cells with [
3H]palmitate followed by
immunoprecipitation and SDS-PAGE. As seen in Figure 5B,
the immunoprecipitation of full-length mucolipin-1 revealed
a band of approximately 90 kDa that corresponds to the
predicted molecular weight of the chimera and was labeled
with [
3H]palmitate. In contrast, no metabolic labeling was
observed for the MLN-GFP-C
565CC/AAA mutant. Therefore,
we conclude that mucolipin-1 is palmitoylated in vivo
Table 1: Mutational analysis of the C-terminal tail of mucolipin-1
Sequence Membrane association Localization
A
560CSLLCCCGRDPSEEHSLLVN þþþ Endosomes/plasma membrane
A
560ASLLCCCGRDPSEEHSLLVN þþþ Endosomes/plasma membrane
A
560CALLCCCGRDPSEEHSLLVN þþþ Endosomes/plasma membrane
A
560CSAACCCGRDPSEEHSLLVN – Cytosol
A
560CSALCCCGRDPSEEHSLLVN þþþ Endosomes/plasma membrane
A
560CSLACCCGRDPSEEHSLLVN – Cytosol
A
560CSLLAAAGRDPSEEHSLLVN – Cytosol
A
560CSLLACCGRDPSEEHSLLVN –/þ Cytosol/endosomes/plasma membrane
A
560CSLLCACGRDPSEEHSLLVN – Cytosol
A
560CSLLCCAGRDPSEEHSLLVN –/þ Cytosol/endosomes/plasma membrane
A
560CSLLCCC þþþ Plasma membrane
A
560CSLLCCCGRDPSEEHSAAVN þþþ Plasma membrane
Wild-type GFP-MLN-CTail or GFP-MLN-CTail carrying the indicated mutations (in red) was expressed in HeLa cells, and their association
with membranes was assayed by immunofluorescence microscopy.
Trafficking of Mucolipin-1 to Lysosomes
Traffic 2006; 7: 337–353 343and that Cys565, Cys566 and Cys567 account for the total
palmitoylation of the protein.
Full-length mucolipin-1 contains additional sorting
information that regulates its transport to lysosomes
We next analyzed the distribution of full-length mucolipin-1.
To do so, we generated a chimera in which GFP was
fused to the C-terminal end of mucolipin-1 (MLN-GFP).
When transiently transfected into HeLa cells, MLN-GFP
localized in vacuolar structures containing late endosomal–
lysosomal markers such as CD63 and lamp-1 (Figure 6). In
contrast, no significant co-localization with early endoso-
mal markers was observed (data not shown). This distri-
bution is consistent with recent data showing that cup-5,
the C. elegans ortholog of mucolipin-1, is present in both
mature lysosomes and specific subdomains of late endo-
somes where endosomal cargo destined for the lysosome
accumulates (21). In addition, Manzoni et al. (26) have
recently described that a myc-epitope tagged version of
mucolipin-1 mostly co-localizes with lamp-1. It has been
suggested that mucolipin-1 could play an important role in
the regulation of lysosomal biogenesis. In agreement with
thisidea, we foundthat the over-expression ofMLN-GFP in
HeLa cells caused a dramatic enlargement of lysosomes.
These structures resemble the late endosome–lysosome
hybrid organelles observed in cup-5-defective cells (see
arrows in Figure 6). Interestingly, very little co-localization
was observed between Tac-MLN-CTail and MLN-GFP,
indicating that additional sorting information, located in
a region different from the C-terminal tail, mediates the
transport of the full-length mucolipin-1 to lysosomes.
The N-terminal cytoplasmic tail of mucolipin-1
contains targeting information for sorting to
lysosomes
The search for sorting sequences that mediate the deliv-
ery of mucolipin-1 to lysosomes revealed the presence of
a (D/E)XXXL(L/I) motif (E
11TERLL) at the N-terminal cyto-
solic tail of the protein that could potentially mediate inter-
action with APs and transport to lysosomes. To determine
whether this motif is in fact functional, we fused the
N-terminal tail of mucolipin-1 (residues from positions 1
to 66) to the extracellular and transmembrane domains of
Tac, and the distribution of the resulting chimera (Tac-
MLN-NTail) was analyzed by confocal microscopy. As
shown in Figure 7A, Tac-MLN-NTail localized predomi-
nantly to large vesicular structures within the cytoplasm.
To determine the nature of these vesicles, we monitored
EGF uptake using EGF-Alexa Fluor 555. EGF binds to its
receptor on the cell surface, and receptor–ligand com-
plexes are internalized by clathrin-coated vesicles and
transported to lysosomes for degradation. After uptake
for 30 min, EGF labeled small vesicles throughout the
cytoplasm that correspond to early and/or late endosomes
and did not contain Tac-MLN-NTail. In contrast, after 3 h of
internalization, EGF accumulated at lysosomes and
showed good co-localization with Tac-MLN-NTail.
Extensive co-localization was also observed between
Tac-MLN-NTail and MLN-GFP. These results indicate that
the N-terminal tail of mucolipin-1 contains sorting informa-
tion for transport to lysosomes.
To be sure that the cloning of the N-terminal tail fused to
Tac in a ‘type I’ orientation (instead of the ‘type II’ con-
formation that this fragment has in mucolipin-1) was not
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Figure 5: Effect of palmitoylation on the internalization of Tac-
MLN-CTail. (A) Internalization of Tac, Tac-MLN-CTail and Tac-MLN-
CTail-C
565CC/AAA was analyzed by FACS, as described in Materials
and Methods. Results are expressed as the percentage of Tac
chimera remaining at the cell surface after 15 min incubation at
37  C. The graphic shows the average results from four indepen-
dent experiments. (B) HeLa cells transfected with MLN-GFP
or MLN-GFP-C
565CC/AAA were metabolically labeled with
[
3H]palmitic acid for 6 h. Cells were then lysed, immunoprecipitated
with an anti-GFP polyclonal antibody, subjected to SDS-PAGE and
analyzed either by Western blotting using an anti-GFP monoclonal
antibody (left panel) or by fluorography and autoradiography (right
panel).Filmwasexposedfor15daysat  80  C.Arrowcorresponds
to the predicted molecular weight of the monomeric form of the full-
length MLN-GFP fusion protein, whereas the asterisk corresponds
to a putative proteolytic form. Higher bands probably correspond to
dimers and oligomers of MLN-GFP.
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344 Traffic 2006; 7: 337–353affecting the sorting of the chimera, we generated a con-
struct in which the NTail of mucolipin-1 was fused to the
transmembrane and extracellular domains of the transfer-
rin receptor (TfR). Our data showed that the MLN-NTail-
TfR-GFP chimera is partially delivered to lysosomes (as
seen by co-localization with lamp-1), whereas wild-type
TfR-GFP localizes at early endosomes and plasma mem-
brane (data not shown). These results corroborate the
presence of lysosomal sorting motifs at the N-terminal
tail and indicate that the transport of Tac-MLN-NTail to
lysosomes is not a consequence of the ‘reverse’ orienta-
tion of the chimera.
One interesting observation from our previous experiment
was that Tac-MLN-NTail could only be detected after incu-
bation of the cells with the lysosomal inhibitor leupeptin.
This suggests that after the synthesis of the protein, Tac-
MLN-NTail is rapidly transported to lysosomes for degra-
dation. To test this hypothesis, we followed the fate of
newly synthesized Tac-MLN-NTail by performing ‘pulse–
chase’ experiments by treatment with Brefeldin A (BFA).
This approach has been recently used to monitor the
transport of LEP100 and CD63 to lysosomes (27). HeLa
cells were transfected with the Tac-MLN-NTail or the
Tac-MLN-CTail chimera, and 6 h after transfection, the
Tac-MLN-CTail MLN-GFP merge
CD63 MLN-GFP merge
Lamp1 MLN-GFP merge
Figure 6: Full-length mucolipin-1 contains additional sorting signals that regulate its transport to lysosomes. HeLa cells were
transfected with MLN-GFP alone (second and third row) or in combination with Tac-MLN-CTail (first row). Fifteen hours after transfection,
cells were incubated with 100 mg/mL of cycloheximide for 6 h to allow efficient exit from the ER, fixed, permeabilized and immunostained with
the indicated antibodies. MLN-GFP is in green; Tac-MLN-Tail, lamp-1 and CD63 are in red; yellow indicates co-localization. Bar represents 10 mm.
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A
B
merge
Alexa-EGF 3 h Tac-MLN-NTail merge
MLN-GFP Tac-MLN-NTail
Tac-MLN-NTail 4 h Tac-MLN-NTail 0 h Tac-MLN-NTail 4 h + leupeptin
Tac-MLN-CTail 4 h Tac-MLN-CTail 0 h Tac-MLN-CTail 4 h + leupeptin
merge
Figure 7: The N-terminal tail of mucolipin-1 contains sorting information for transport to lysosomes. (A) HeLa cells expressing Tac-
MLN-NTail (green) were incubated with Alexa555-EGF for 10 min, washed and allowed to internalize for 30 min to load early–late endosomes
(first row), or for 3 h to stain lysosomes (second row) in the presence of 20 mM leupeptin. The third row shows HeLa cells co-expressing Tac-
MLN-NTail and MLN-GFP treated for 5 h with 100 mg/mL of cycloheximide and 20 mM leupeptin. Refer to Figure 8B for schematics of the
chimeras. (B) HeLacells were transfected with Tac-MLN-NTail(firstrow) orTac-MLN-Ctail(second row).Six hours aftertransfection, the cells
were incubated for an additional 12 h in the presence of 2 mg/mL of Brefeldin A (BFA). BFA was then removed, and the cells were incubated
for the indicated periods of time at 37  C in the absence or presence of 20 mM leupeptin. Cells were fixed and permeabilized, and the
distribution of the chimeras was revealed by indirect immunofluorescence staining and confocal microscopy. Bars represent 10 mm.
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accumulate the newly synthesized proteins in the endo-
plasmic reticulum (ER) (28). Proteins were then released
from the ER by incubation in medium without BFA, and
cells were analyzed at different time-points. We found
that, whereas the levels of Tac-MLN-CTail remained
stable, most of Tac-MLN-NTail labeling disappeared after
a 4-h chase. As expected, the degradation of Tac-MLN-
NTail was inhibited in the presence of leupeptin, indicating
that the degradation of the protein occurs at lysosomes
(Figure 7B).
It is important to note that during the BFA ‘pulse–chase’
experiments we observed that most of Tac-MLN-CTail
reaches the plasma membrane before its location at
early endosomes. In contrast, we did not detect Tac-
MLN-NTail at the plasma membrane at any time, suggest-
ing that the chimera travels directly from the TGN to the
endosomal–lysosomal system. In agreement with this
idea, the distribution of Tac-MLN-NTail did not change in
cells treated with siRNA against AP2, thus suggesting that
the chimera does not travel via the plasma membrane en
route to lysosomes. In contrast, most of Tac-MLN-CTail
accumulated at the plasma membrane in the absence of
AP2 (Supplementary Material, Figure).
To determine whether Tac-MLN-NTail passes through
early endosomes, we co-expressed the Tac-MLN-NTail
chimera together with the constitutively active form of
Rab5 (Rab5-Q79L-GFP). It is known that the over-
expression of Rab5-Q79L results in enlarged endosomes
and interferes with both receptor-mediated and fluid-
phase endocytosis (29,30). As seen in Figure 8A, the
over-expression of Rab5-Q79L caused the retention of
Tac-MLN NTail in early endosomes allowing the detection
of the chimera for long periods of time in the absence of
leupeptin.
Finally, we addressed whether the (D/E)XXXL(L/I) motif
located at the N-terminal tail is responsible for the target-
ing of Tac-MLN-NTail to lysosomes. As seen in Figure 8B,
the mutation of Leu15 and Leu16 to alanines (Tac-MLN-
NTail-L
15L/AA) abolished the delivery of the resulting
chimera to lysosomes, instead causing it to accumulate
predominantly at the plasma membrane. These results
indicate that the E
11TERLL sequence acts as a lysosomal
targeting motif regulating the transport of the Tac-MLN-
NTail protein from the TGN to lysosomes via early
endosomes.
Two di-leucine motifs regulate the transport of
mucolipin-1 to lysosomes
The data described above allowed us to conclude the
existence of two different sorting motifs, an internalization
motif and a lysosomal targeting motif located at the C- and
N-terminal tails, respectively. To determine whether these
sequences are functional in the context of the full-length
protein or whether one of the motifs is preferred, we
mutated each of the di-leucine pairs and analyzed the
distribution of the resulting proteins by confocal micro-
scopy. Figure 9A shows that the mutation of neither
Leu15Leu16 (MLN-GFP-L
15L/AA) nor Leu577Leu578
(MLN-GFP-L
577L/AA) pair to alanines prevented MNL-
GFP from reaching lysosomes (as seen by co-localization
with lamp-1, Supplementary Material, Figure S4).
However, simultaneous mutation of both di-leucine pairs
(MLN-GFP-L
15L/AA-L
577L/AA) resulted in the accumulation
of MLN-GFP at the plasma membrane.
Interestingly, the over-expression of Rab5-Q79L-GFP
caused a very clear accumulation of MLN-RFP, as well as
MLN-RFP-L
15L/AA and MLN-RFP-L
577L/AA, into Rab5-
Q79L-GFP-positive structures indicating that, independently
of the route used, mucolipin-1 travels through early
endosomes on its way to lysosomes (Figure 9B).
Finally, we addressed whether palmitoylation plays a role
in the sorting of full-length mucolipin-1. Data showed that
the mutation of the palmitoylation signal alone (MLN-GFP-
C
565CC/AAA) did not have a clear effect on the trafficking
of the protein, as the distribution of MLN-GFP-C
565CC/
AAA resembled that of MLN-GFP. However, the mutation
of Cys565, Cys566 and Cys567 in the MLN-GFP-L
15L/AA
mutant (MLN-GFP-L
15L/AA-C
565CC/AAA) or the treatment
of MLN-GFP-L
15L/AA with 2-BP caused a clear accumula-
tion of the chimeras at the plasma membrane
(Supplementary Material, Figure).
In conclusion, our results indicate that either one of the
di-leucine motifs can mediate the sorting of mucolipin-1
to lysosomes and reveal a role for palmitoylation in the
regulation of the protein trafficking.
Discussion
In this study, we have identified two targeting motifs that
mediate the trafficking of mucolipin-1 to lysosomes
(Figure 10). Both sorting signals are conventional acidic
di-leucine motifs ((D/E)XXXL(L/I)) and are located in sepa-
rate protein domains. One di-leucine motif (E
11TERLL) is
situated in the N-terminal cytosolic tail and mediates trans-
port to lysosomes when attached to the reporter protein
Tac. The other di-leucine motif (E
573EHSLL) is positioned
at the end of the C-terminal tail and functions as an
internalization motif. Interestingly, the mutation of either
di-leucine motif alone is not sufficient to prevent the
delivery of full-length MLN-GFP to lysosomes. However,
simultaneous mutation of both motifs caused the accumu-
lation of MLN-GFP at the plasma membrane.
It has been reported that the trafficking of newly synthe-
sized lysosomal membrane proteins from the TGN to lyso-
somes may occur through a direct (from TGN to either
early or late endosomes, and then to lysosomes) or an
indirect pathway (from TGN to plasma membrane
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endosomes, late endosomes and lysosomes). In the case
of mucolipin-1, one might predict that the mutation of its
lysosomaltargetingsequencewouldcausethedefaultdeliv-
ery of mucolipin-1 to the plasma membrane from where it
would be internalized and delivered to endosomes due to
the internalization motif located at the C-terminal tail. In
agreement with this idea, MLN-GFP-L
15L/AA was able to
reach lysosomes but showed clearplasma membrane stain-
ing when compared with MLN-GFP. This accumulation at
Tac
(D/E)XXXL(L/I)
Lumenal
Rab5-Q79L-GFP Tac-MLN-NTail
Tac-MLN-NTail Tac-MLN-NTail L15L/AA
merge
TM Cyt COOH H2N-
A
B
Tac-MLN-NTail
Tac-MLN-NTail L15L/AA
Figure 8: Mutation of a di-leucine motif located at N-terminal tail of mucolipin-1 causes mistargeting of a Tac-MLN-NTail
chimera to the plasma membrane. (A) HeLa cells were transfected with Tac-MLN-NTail (red) in combination with Rab5-Q79L-GFP.
Leupeptin (20 mM) was added 4 h before fixation of the cells, and the distribution of the chimeras was revealed by indirect immuno-
fluorescence staining and confocal microscopy. (B) HeLa cells expressing wild-type Tac-MLN-NTail or Tac-MLN-NTail carrying alanine
mutations at the di-leucine motif (Tac-MLN-NTail-L
15L/AA) was analyzed by indirect immunofluorescence staining and confocal micro-
scopy. Sequence of the wild-type and mutated NTail of mucolipin-1 and position of the di-leucine motif are shown above the panels. Bars
represent 10 mm.
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A
B
MLN-GFP-L15L/AA
MLN-GFP-L577L/AA MLN-GFP-L15L/AA-L577L/AA
Rab5-Q79L-GFP MLN-RFP merge
Rab5-Q79L-GFP MLN-RFP-L15L/AA merge
Rab5-Q79L-GFP MLN-RFP-L577L/AA merge
Figure 9: Both di-leucine motifs
are required for targeting of
mucolipin-1 to lysosomes. (A)
Wild-type MLN-GFP or MLN-GFP
carrying the indicated mutations
was transiently expressed in HeLa
cells. Cycloheximide was added for
the last 6 h of transfection; cells
were then fixed and analyzed by
confocal microscopy. (B) Wild-type
mucolipin, or the indicated mucolipin
mutants, was fused to red fluores-
cent protein DsRed-Monomer (RFP)
and coexpressed with Rab5-Q79L-
GFP. Fifteenhours aftertransfection,
cells were treated with cyclo-
heximide for 6 h and analyzed by
confocal microscopy. Bars represent
10 mm.
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of newly synthesized MLN-GFP-L
15L/AA from TGN to
plasma membrane, although enhanced recycling of this
mutant from endosomes to plasma membrane cannot be
ruled out. Once at endosomes, transport to late endosomes
and lysosomes could occur by default. Alternatively, extra-
cellular or membrane-spanning domains could also partici-
pate in lysosomal sorting (31). The mutation of the
internalization motif (MLN-GFP-L
577L/AA) did not cause accu-
mulation at the plasma membrane, indicating that the protein
can reach lysosomes through an exclusively intracellular or
direct route. Although we cannot rule out the presence of
additional internalization motifs at the N-terminal tail or
within other intracellular loops, the complete block of the
double mutant at the plasma membrane strongly argues
against this possibility. Finally, the mutation of both di-
leucine motifs (MLN-GFP-L
15L/AA-L
577L/AA) caused the
delivery of the newly synthesized protein to the plasma
membrane where it accumulated because it was unable to
internalize.
In addition, we cannot discard the possibility that both N-
and C-terminal di-leucines are acting as internalization
motifs and that the different distribution of the Tac-MLN-
NTail and Tac-MLN-CTail chimeras is a consequence of
the N-terminal di-leucine being more efficient at mediating
sorting at early endosomes. However, the failure to
observe Tac-MLN-NTail at the plasma membrane in our
BFA ‘pulse–chase’ and, more importantly, the lack of the
accumulation of Tac-MLN-NTail at the plasma membrane
in cells depleted of AP2 are more consistent with the
hypothesis that the N-terminal di-leucine motif mediated
direct transport from TGN to early endosomes (probably
through interaction with AP1) and subsequent delivery
from early endosomes to lysosomes (most likely due to
interactions with AP3). Therefore, our results suggest that
mucolipin-1 may use both direct and indirect routes to
reach lysosomes.
It would be interesting to measure the fraction of newly
synthesized mucolipin-1 that traffics via the plasma mem-
brane. However, initial attempts by our laboratory to place
a FLAG epitope at the first extracellular loop of mucolipin-1
or to detect biotinylated mucolipin-1 at the plasma mem-
brane were unsuccessful. Nevertheless, the fact that
MLN-GFP-L
577LAA does not significantly accumulate at
the surface suggests that the direct route plays a major
role in the sorting of mucolipin-1. Another possibility is that
the internalization motif participates in alternative pro-
cesses. For example, the exocytic fusion of lysosomes
with the plasma membrane (32) could generate a pool of
mucolipin-1 that should be quickly retrieved to lysosomes.
Palmitoylation is one of the most common post-
translational modifications found in proteins and has been
implicated in the regulation of membrane association,
trafficking, protein–protein interaction and enzyme activity
(33,34). Because of its reversibility, palmitoylation is a
suitable mechanism to regulate the function of integral
and peripheral membrane proteins. Treatment with palmi-
toylation inhibitors, mutation of specific cysteine residues
and metabolic labeling with [
3H]palmitate led us to con-
clude that the C-terminal tail of mucolipin-1 is palmitoy-
lated. The mutation of either of the cysteine residues in
the sequence L
564CCC impaired the association of GFP-
MLN-CTail with membranes, although the effect was
more apparent when Cys566 was mutated to alanine.
With the current data, we cannot determine whether all
three cysteines are palmitoylated or whether the muta-
tions of Cys565 and Cys567 affect the optimal palmitoyla-
tion of Cys566. It has recently been described that
hydrophobic residues neighboring a cysteine can also
influence palmitoylation. For example, the substitution of
certain leucine residues with alanine abolishes palmitoyla-
tion of eNOS (35) and PSD95 (36). Consistently, the muta-
tion of Leu564 to alanine also inhibited GFP-MLN-CTail
palmitoylation, thus confirming the importance of residues
adjacent to cysteines in the process.
Our data reveal that palmitoylation may be an important
factor in the regulation of integral membrane protein endo-
cytosis. Recently several groups have suggested that the
internalization of a number of receptors such as CC chemo-
kine receptor CCR5 (37), membrane-type matrix metallo-
proteinase-1 (38), and luteinizing hormone receptor (39)
might also be regulated by palmitoylation. In the case of
mucolipin-1, we propose that palmitoylation may promote
internalization by bringing the C-terminal endocytosis motif
closer to the plasma membrane, thus facilitating its inter-
action with AP2. Therefore, our results suggest that palmi-
toylation could regulate the efficiency of internalization of
di-leucine motifs located at the end of long cytosolic tails.
Finally, we cannot rule out the possibility that palmitoylation
of mucolipin-1 has additional roles in regulating the traffic or
Transmembrane domain
Palmitoylation
Transient receptor potential
Cytosol
NH
LL
COOH LL CCC
Figure 10: Schematic illustration of the proposed topology
of mucolipin-1. Mucolipin-1 has six predicted transmembrane
domains, with the N- and C-terminal tails residing in the cyto-
plasm. The transient receptor potential channel domain is in
green. The sorting motifs identified in this study are represented
in blue. Protein is depicted as palmitoylated and associated with
membranes at the C-terminal palmitoylation site.
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make other determinants in the C-terminal tail accessible,
promoting interactions with different effectors.
In conclusion, our data provide novel information toward
understanding the intracellular pathways used by mucoli-
pin-1 for targeting to lysosomes and emphasize the diver-
sity of sorting mechanisms utilized in trafficking of
lysosomal proteins.
Materials and Methods
Antibodies and reagents
The following antibodies were used: mouse monoclonal anti-EEA1 (BD
Transduction Laboratories, San Jose, CA, USA), mouse monoclonal anti-
CD63 (H5C6; Pharmingen, San Jose, CA, USA), mouse monoclonal anti-b
subunit of AP2 (100/2; Sigma-Aldrich, St Louis, MO, USA), rabbit anti-GFP
(MBL International, Woburn, MA, USA), mouse monoclonal anti-GFP
(ab1218; Abcam, Cambridge, MA, USA), mouse monoclonal anti-IL2
Receptor alpha (Tac) (143–13; Abcam) and mouse monoclonal anti-
annexin-II (Zymed, San Francisco, CA, USA). A polyclonal antibody to Hrs
was the kind gift of S. Urbe (University of Liverpool, Liverpool, UK) (40).
Mouse monoclonal anti-lamp-1 (Ac17) was obtained from E. Rodriguez-
Boulan (Weill Medical College of Cornell University) (41).
Cycloheximide, 2-BP, leupeptin, BFA and protease inhibitor cocktail were
obtained from Sigma (St Louis, MO, USA). Rhodamine-transferrin and
Alexa555-EGF were supplied by Molecular Probes (Eugene, OR, USA).
[
3H]Palmitate acid (30–60 Ci) was obtained from Perkin-Elmer (Boston,
MA, USA).
Plasmids
The complete open reading frame of human mucolipin-1 was PCR ampli-
fied from a human brain cDNA library using specific primers and cloned into
the pEGFP-N1 and pDs-Red-Monomer-N1 vectors (Clontech, Palo Alto, CA,
USA). To generate the Tac chimeric constructs, we amplified the amino
(amino acids 1–66) or carboxyl (amino acids 518–580) cytosolic tails of
mucolipin-1 by PCR and cloned between an XbaI site inserted at the 3´
end of the Tac cDNA and the BamHI site from the expression vector pCDL-
SRa (42). The coding region of the Tac chimeras was then subcloned into
the HindIII–BamHI sites of the eukaryotic expression vector pcDNA3.1 (þ)
(Invitrogen, San Diego, CA, USA). The C-terminal cytosolic tail (amino acids
518–580) of mucolipin-1 was cloned into the EcoRI and SalI sites of the
pEGFP-C2 vector. Rab5-GFP and Rab5-GFP-Q79L are from R. Lodge
(Laval, Quebec, Canada). AP2-GFP was obtained from L. Greene
(National Institutes of Health, Bethesda, MD, USA) (43). Mutations of
residues in the cytosolic tails of mucolipin-1 were introduced using the
QUICKCHANGE site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA).
SiRNA
RNAi of the m2 subunit of the AP2 complex targeting the sequence
GUGGAUGCUUUCGGGUCA was designed and synthesized as Option C
by Dharmacon Research (Lafayette, CO, USA). Two consecutive transfec-
tions were carried out every 72 h in HeLa cells according to the manufac-
turer’s instructions.
Transfection and immunofluorescence microscopy
The transfection of HeLa cells was performed using FuGENE-6 (Roche
Molecular Biochemicals, Indianapolis, IN, USA). For immunofluorescence,
transfected HeLa cells were grown on coverslips, fixed in methanol/acet-
one (1 : 1 v/v) for 10 min at  20  C and subsequently air-dried. Incubation
with primary antibodies diluted in phosphate-buffered saline (PBS), 0.1%
(w/v) saponin, 0.1% bovine serum albumin (BSA), was carried out for 1 h at
room temperature. Unbound antibodies were removed by rinsing with PBS
for 5 min, and cells were subsequently incubated with a secondary
antibody diluted in PBS, 0.1% (w/v) saponin, 0.1% BSA, for 30–60 min at
room temperature. After a final rinse with PBS, coverslips were mounted
onto glass slides with Fluoromount G (Southern Biotechnology Associates,
Birmingham, AL, USA). Fluorescence images were acquired on an LSM
510 confocal microscope (Carl Zeiss, Thornwood, NY, USA).
To analyze trafficking of newly synthesized Tac chimeras, we transfected
HeLa cells grown on coverslips with the corresponding cDNA for 6 h and
then incubated with 2 mg/mL of BFA (Sigma-Aldrich) for 12 h to accumu-
late the newly synthesized proteins in the ER. The cells were then washed
and incubated for different times at 37  C in regular culture medium in the
absence or presence of 20 mM leupeptin, fixed, permeabilized and analyzed
by confocal microscopy.
Internalization assays
Internalization assays were carried out by incubation of transfected HeLa
cells on ice for 1 h with an antibody against the extracellular domain of Tac
diluted in PBS. The cells were washed extensively, incubated for 15 min at
37  C in regular culture medium, fixed in methanol/acetone and incubated
with a Cy3-conjugated anti-mouse IgG diluted in PBS, 0.1% (w/v) saponin,
0.1% BSA, for 30–60 min at room temperature. After a final rinse with
PBS, coverslips were mounted onto glass slides with Fluoromount G
(Southern Biotechnology Associates). Fluorescence images were acquired
on an LSM 510 confocal microscope (Carl Zeiss).
Quantitative internalization assay
HeLa cells (1   10
6) were transiently transfected with the corresponding
Tac chimera. Sixteen hours after transfection, cells were harvested in
Cellstripper
TM solution (Cellgro, Mediatech, Inc., Herndon, VA), washed
once with cold PBS and incubated with anti-Tac antibody in PBS on ice
for 60 min. After extensive washes, cells were split into two aliquots; one
aliquot was directly fixed with 2% paraformaldehyde (time 0), and the
other was incubated for 15 min at 37  C, to allow cell-surface-bound anti-
bodies to internalize before fixation. Cells were then stained with a fluor-
escein isothiocyanate-conjugated goat anti-mouse secondary for 30 min on
ice, washed and analyzed by flow cytometry using a FACS-Calibur and
CELLQUEST software (BD Biosciences, San Jose, CA, USA). Amounts of
each chimeric protein remaining on the cell surface were defined as the
specific fluorescence value, which was calculated after subtracting the
mean fluorescence value of non-transfected cells from that of transfected
cells. Percent internalization for each chimeric construct was calculated
using the specific mean fluorescence value of cells fixed at time 0 as
100%. Results were expressed as the mean   SD of at least three inde-
pendent experiments. Measurements of forward scatter were used to
exclude dead cells and debris.
Fractionation of HeLa cells and immunoblot
HeLa cells were transfected with GFP-MLN-CTail in the presence of etha-
nol (vehicle) or 50 mM of 2-BP and homogenized in HES buffer (20 mM
Hepes, 250 mM sucrose, 1 mM EDTA, pH 7.4) supplemented with pro-
tease inhibitors. Postnuclear supernatants were separated by centrifuga-
tion at 196 000   g for 60 min to yield cytosol (supernatant) and
membranes (pellet) fractions.
Immunoblotting was carried out according to standard procedures.
Proteins were separated by SDS-PAGE and transferred to nitrocellulose.
The membrane was then blocked with PBS/0.05% Tween-20/10% dry milk
and incubated with the indicated antibody. Enhanced chemiluminescence
reagent (Amersham Bioscience, Piscataway, NJ, USA) was used for
detection.
Metabolic labeling with [
3H]palmitic acid
Cells transfected with MLN-GFP or MLN-GFP-C
565CC/AAA for 24 h were
washed twice with serum-free DMEM and labeled in 1.5 mL of DMEM
containing 5% FBS, 20 mM Hepes pH 7.4 and 600 mCi of [
3H]palmitic acid
for 6 h at 37  C. Cells were then washed with ice-cold PBS and lysed in
TNE buffer (25 mM Tris, 150 mM NaCl, 5 mM EDTA, 1% Triton-X-100,
pH 7.4) supplemented with protease inhibitors. The lysate was precleared
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and protein G–Sepharose (Amersham Bioscience). Immunoprecipitates
were collected, washed four times with PBS, eluted by incubation with
Laemmli sample buffer for 10 min at room temperature and analyzed in
two identical gels by SDS-PAGE under reducing conditions. One gel was
fixed, treated with Amplify (Amersham Bioscience), dried and exposed to
Kodak X-AR film for 15 days to visualize radiolabeled proteins, and the
other gel was subjected to immunoblot analysis using the anti-GFP mono-
clonal antibody.
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Supplementary Material
Figure S1. The C-terminal tail of mucolipin-1 does not co-localize
with late endosomal–lysosomal markers. HeLa cells expressing
Tac-MLN-CTail (red) were incubated with Alexa488-EGF for
10 min, washed and allowed to internalize for 2 h to load late
endosomes (first row). The second row shows HeLa cells co-
expressing Tac-MLN-CTail and Vamp7-GFP (lysosomal marker).
Note that Tac-MLN-CTail has very little co-localization with both
markers. Bar represents 10 mm.
Figure S2. The C-terminal tail of mucolipin-1 associates with
intracellular membranes. HeLa cells were transfected with GFP-
MLN-CTail either alone or in combination with the Tac-MLN-CTail
chimera (fourth row). Transfected cells were fixed, permeabilized,
immunostained with the indicated antibodies and examined by
confocal fluorescence microscopy. For transferrin staining, cells
were incubated with rhodamine-transferrin for 15 min at 37  C.
GFP-MLN-CTail is in green; transferrin, EEA1, Hrs and Tac-MLN-
Tail are in red; yellow indicates co-localization. Bar represents
10 mm.
Figure S3. The Tac-MLN-NTail chimera does not reach the
plasma membrane in its way to lysosomes. (A) HeLa cells treated
with control (non-silencing) siRNA or siRNA targeted to the m2
subunit of the AP2 complex were transfected with either Tac-
MLN-CTail or Tac-MLN-NTail. Leupeptin (20 mM) was added 4 h
before fixation of the cells, and the distribution of the chimeras
was revealed by indirect immunofluorescence and confocal
microscopy analysis. Bar represents 10 mm. (B) Quantification of
cells treated with non-silencing siRNA or AP2 siRNA in which the
corresponding chimera was localized mainly at the plasma mem-
brane (PM) in the presence or absence of leupeptin. One hundred
cells were counted for each condition.
Figure S4. Co-localization of mucolipin-1 wild-type and mucoli-
pin-1 mutants with lysosomal markers. HeLa cells were trans-
fected with MLN-GFP wild-type or the indicated mutants.
Transfected cells were fixed, permeabilized, immunostained
with an antibodies against lamp-1 and examined by confocal
fluorescence microscopy. Yellow indicates co-localization. Bar
represents 10 mm.
Figure S5. Role of palmitoylation in the trafficking of full-length
mucolipin-1. HeLa cells were transfected with either MLN-GFP-
L
15L/AA, in the presence of ethanol or the inhibitor of
palmitoylation 2-bromopalmitate (2-BP) (upper panels), or with
MLN-GFP carrying the C
565CC/AAA mutation alone or in combina-
tion with L
15L/AA (lower panels) and analyzed by confocal micro-
scopy. Bar represents 10 mm.
These materials are available as part of the online article from
http://www.blackwell-synergy.com
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